Search Results - BRUGAROLAS, ANTONIO
-
1
RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer
Published in BMC cancer (20-04-2021)“…Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53 somatic alterations in a variable percentage of tumors throughout all molecular…”
Get full text
Journal Article -
2
Psycho-Oncological Intervention Through Counseling in Patients With Differentiated Thyroid Cancer in Treatment With Radioiodine (COUNTHY, NCT05054634): A Non-randomized Controlled Study
Published in Frontiers in psychology (25-02-2022)“…Diagnosis and treatment of differentiated thyroid carcinomas (DTC) cause anxiety and depression. Additionally, these patients suffer hormonal alterations that…”
Get full text
Journal Article -
3
Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies
Published in Frontiers in oncology (24-06-2022)“…Therapeutic monoclonal antibodies (mAbs), including immune checkpoint inhibitors (ICIs), are an important breakthrough for the treatment of cancer and have…”
Get full text
Journal Article -
4
Polymorphisms of the Repeated Sequences in the Enhancer Region of the Thymidylate Synthase Gene Promoter May Predict Downstaging After Preoperative Chemoradiation in Rectal Cancer
Published in Journal of clinical oncology (15-03-2001)“…Thymidylate synthase (TS) is an important target enzyme for the fluoropyrimidines. TS gene promoter possesses regulatory tandemly repeated (TR) sequences that…”
Get full text
Journal Article -
5
Therapeutic Drug Monitoring of Erlotinib in Non-Small Cell Lung Carcinoma: A Case Study
Published in Therapeutic drug monitoring (01-08-2021)“…We describe a clinical case of an 84-year-old man diagnosed with non-small cell lung carcinoma and epidermal growth factor receptor mutation, who was treated…”
Get full text
Journal Article -
6
Therapeutic drug monitoring of nivolumab in clinical practice: Preliminary experience
Published in Journal of clinical oncology (20-05-2019)“…Abstract only e14089 Background: Fixed dose schemes, regardless of body weight, have been accepted by the regulatory agencies for the PD-1 targeting…”
Get full text
Journal Article -
7
A novel genomic signature predicting FDG uptake in diverse metastatic tumors
Published in EJNMMI research (18-01-2018)“…Background Building a universal genomic signature predicting the intensity of FDG uptake in diverse metastatic tumors may allow us to understand better the…”
Get full text
Journal Article -
8
Therapeutic Drug Monitoring of Erlotinib in Non-Small Cell Lung Carcinoma: A Case Study
Published in Therapeutic drug monitoring (05-04-2021)Get full text
Journal Article -
9
Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) in routine practice in an oncology service. preliminary results
Published in Journal of clinical oncology (20-05-2018)“…Abstract only…”
Get full text
Journal Article -
10
A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin Analogs
Published in Clinical nuclear medicine (01-09-2016)“…ABSTRACTWe present a sarcoma patient with a tumor reduction of more than 50% in lung metastasis after 2 single courses of the investigational medical product…”
Get full text
Journal Article -
11
Cross-communication between Gi and Gs in a G-protein-coupled receptor heterotetramer guided by a receptor C-terminal domain
Published in BMC biology (28-02-2018)“…BACKGROUNDG-protein-coupled receptor (GPCR) heteromeric complexes have distinct properties from homomeric GPCRs, giving rise to new receptor functionalities…”
Get full text
Journal Article -
12
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer
Published in Oncology (01-01-2003)“…Paclitaxel-cisplatin is considered to be a standard therapy for metastatic non-small-cell lung cancer (NSCLC). The aim of this study was to evaluate the…”
Get more information
Journal Article -
13
Immunological profile could be responsible of the unusual long-lasting cutaneous-only breast cancer recurrence: An observational study
Published in Journal of clinical oncology (01-06-2022)“…e13000 Background: A small number of breast cancer patients develops long-lasting loco-regional cutaneous recurrent disease with a delayed appearance of…”
Get full text
Journal Article -
14
Colorectal Carcinomas and PTEN/MMAC1 Gene Mutations
Published in Clinical cancer research (01-12-2001)“…Purpose: PTEN/MMAC1/TEP1 is a tumor suppressor gene encoding a dual-specificity protein phosphatase with homology to the cytoskeleton proteins, chicken tensin…”
Get full text
Journal Article -
15
Abstract 4648: Development and validation of an HPLC-UV method for Sirolimus (sir) quantification in human blood and application to cancer patients in routine clinical practice
Published in Cancer research (Chicago, Ill.) (01-10-2014)“…Background and objective: After oral administration, SIR (mTOR inhibitor) is rapid absorbed with a bioavailability around 14%. SIR is distributed mostly into…”
Get full text
Journal Article -
16
Equilibrative Nucleoside Transporter ENT1 as a Biomarker of Huntington Disease
Published in Neurobiology of disease (01-12-2016)“…Abstract The initial goal of this study was to investigate alterations in adenosine A2A receptor (A2A R) density or function in a rat model of Huntington…”
Get full text
Journal Article -
17
-
18
Abstract 762: Therapeutic drug monitoring of Anthracyclines and Taxanes in chemotherapy of breast cancer patients
Published in Cancer research (Chicago, Ill.) (15-04-2012)“…Background: Anthracyclines (A) and Taxanes (T) remain amongst the most active drugs in breast cancer chemotherapy. However, significant toxicities are…”
Get full text
Journal Article -
19
Transcriptome (RNA next generation sequencing) for personalizing of cancer treatment: A correlation with previous clinical resistance
Published in Journal of clinical oncology (20-05-2021)“…Abstract only e15046 Background: RNA Next Generation Sequencing (transcriptome) is a potential useful tool to predict chemoresistance to available anticancer…”
Get full text
Journal Article -
20
A phase II study of Recchia's immunomodulatory schedule (RIS) as a maintenance therapy in high-risk tumors after a response
Published in Journal of clinical oncology (20-05-2013)“…Abstract only 3074 Background: F. Recchia et al. (Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: A phase II study. Int J…”
Get full text
Journal Article